IP Library Granted Patent US 8,389,692
Granted Patent B2
US 8,389,692 · App. 13/095,098 · Granted Mar 5, 2013

Anti-platelet membrane glycoprotein VI monoclonal antibody

Inventors: Hiroshi Takayama (Ibaraki, JP); Kamon Shirakawa (Tokyo, JP); Shoji Furusako (Tokyo, JP); Yoshitaka Hosaka (Tokyo, JP); Tomokazu Matsusue (Tokyo, JP); Katsuki Naitoh (Tokyo, JP); Yumi Hotta (Tokyo, JP); Tetsushi Kawahara (Tokyo, JP); Motoyasu Honda (Tokyo, JP)
Assignee: Mochida Pharmaceutical Co., Ltd.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,389,692
App. No.
13/095,098
Granted
Mar 5, 2013
Kind
B2
Abstract

The present invention provides an antibody which has the following features, its active fragment, or a derivative thereof: a) It specifically binds to human platelet membrane glycoprotein VI (GPVI); b) The function to activate a platelet and/or the function to induce a thrombocytopenia in vivo are low; and c) It at least partially depletes GPVI on the platelet membrane by contacting with a platelet.

Claims (13)

1. An isolated antibody or antigen-binding fragment thereof that specifically binds to loop 9 in domain 2 of human platelet glycoprotein VI (GPVI) protein, wherein said antibody or antigen-binding fragment thereof comprises a variable heavy chain (VH) with 3 complementarity determining regions (CDR) and a variable light chain (VL) with 3 complementarity determining regions (CDR), comprising the following VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3, respectively of:

(i) SEQ ID NOs: 18, 19, 20, 54, 55 and 56;

(ii) SEQ ID NOs: 24, 25, 26, 60, 61 and 62;

(iii) SEQ ID NOs: 48, 49, 50, 84, 85 and 86;

(iv) SEQ ID NOs: 362, 363, 364, 404, 405, and 406; and

(v) SEQ ID NOs: 365, 366, 367, 407, 408, and 409.

2. The antibody or antigen-binding fragment thereof of claim 1 , which is a chimeric antibody.

3. The antibody or antigen-binding fragment thereof of claim 1 , which is a humanized antibody.

4. The antibody or antigen-binding fragment thereof of claim 1 , wherein its antigen-binding valency is monovalent.

5. The antibody or antigen-binding fragment thereof of claim 1 , which is polyethyleneglycolated (PEGylated).

6. A pharmaceutical composition comprising the antibody or antigen binding fragment thereof of claim 1 , and a pharmaceutically acceptable excipient.

7. The antigen binding fragment according to claim 1 , which is an Fab, Fab′, F(ab′)2, single-chain antibody (scFv), sc(Fv)2, disulfide-stabilized Fv(dsFv), or a diabody.

8. The antibody or antigen-binding fragment according to claim 1 , which is labeled with a labeling substance; conjugated to a radioisotope, protein, peptide, or low molecular weight compound, or fused to another protein or peptide.

Priority Claims (3)
JP 2005-132665 · Apr 28, 2005 · national
JP 2005-348534 · Dec 1, 2005 · national
WO PCT/JP2006/301818 · Jan 27, 2006 · international
Continuity (2)
Division 11912757
Related Publication 20110217318A1 · Sep 8, 2011